Thomas Stewart
Urology · New Bern, NCNPI 1700871704
Payments from drug & device makers
Across 65 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$297
- Medtronic$245
- Astellas Pharma US Inc$219
- Johnson & Johnson$134
- AbbVie$51
- Endo Pharmaceuticals Inc.$46
- plus $337 from 14 others
What the payments were for
- Food & beverage$1,25194%
- Education$796%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 13 | $297 |
| Medtronic | 5 | $245 |
| Astellas Pharma US Inc | 11 | $219 |
| Johnson & Johnson(2 entities) | 12 | $134 |
| AbbVie(2 entities) | 4 | $51 |
| Endo Pharmaceuticals Inc. | 3 | $46 |
| Convatec Inc. | 1 | $44 |
| Antares Pharma, Inc. | 2 | $38 |
| Bayer | 2 | $35 |
| Boston Scientific | 2 | $33 |
| Olympus America Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| AstraZeneca | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $21 |
| Urovant Sciences Inc | 1 | $21 |
| Pfizer | 1 | $17 |
| Axonics, Inc. | 1 | $14 |
| Hollister Incorporated | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $14 |
| Photocure Inc | 1 | $13 |
How this compares
$1,330 in reported general payments places this provider in the 30th percentile of 434 urology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 12 | $6,957 |
| Estradiol | 17 | $2,423 |
| Tamsulosin Hcl | 59 | $708 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $570 |
| Finasteride | 22 | $113 |
| Solifenacin Succinate | 12 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $219 | $6,95712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 434 urology providers in North Carolina.
Other urology in New Bern
- Daniel GeorgeDurham$17.6M
- Robert LippittSmithfield$11.4M
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- John WrennGreensboro$2.9M
- Michael KennellyCharlotte$1.4M
- John KasparRaleigh$1.1M
- Scott MacdiarmidGreensboro$882K
- Glenn PremingerDurham$736K
- Jonathan HamiltonGreenville$695K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.